> ## Content Index
> Fetch the complete content index at: https://adjacent.media/llms.txt
> Use this file to discover other available public pages before exploring further.

# Cancer Drug Pricing Hits $480,000 Annually, Signaling Industry's New Floor
- URL: https://adjacent.media/signals/cancer-drug-pricing-hits-480-000-annually-signaling-industrys-new-floor/
- Published: 2026-08-31T16:17:06.000Z
- Updated: 2026-08-31T16:17:06.000Z
- Description: Revolution Medicines’ Rasonque normalizes half-million-dollar price tags for incremental oncology advances. The drug extends pancreatic cancer survival by months, not years. This pricing reflects a structural shift: pharmaceutical companies extract maximum value from a fragmented U.S.
- Author: Jonathan Greene
- Tags: #signal, theme-commerce, pricing, healthcare economics, drug pricing

Source: [NYT > Business](https://www.nytimes.com/2026/08/31/business/pancreatic-cancer-drug-prices.html?ref=adjacent.media) (paywall)

Revolution Medicines' Rasonque normalizes half-million-dollar price tags for incremental oncology advances. The drug extends pancreatic cancer survival by months, not years. This pricing reflects a structural shift: pharmaceutical companies extract maximum value from a fragmented U.S. healthcare system that lacks price negotiation leverage, and insurance reimbursement rarely questions six-figure annual costs. Payers have stopped resisting ultra-premium pricing, making it the default starting position rather than an outlier. That will cascade through reimbursement expectations across the cancer drug pipeline.